BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

809 related articles for article (PubMed ID: 15651178)

  • 1. Use of newer antifungal therapies in clinical practice: what do the data tell us?
    Perfect JR
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 7):15-23. PubMed ID: 15651178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of invasive mycoses in hematology patients: current approaches.
    Perfect JR
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 7):5-14. PubMed ID: 15651177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Update on therapy of invasive mycoses in hematology and oncology].
    Maschmeyer G; Haas A; Böhme A
    Dtsch Med Wochenschr; 2005 Jun; 130(22):1381-4. PubMed ID: 15915381
    [No Abstract]   [Full Text] [Related]  

  • 4. [symbol: see text]Caspofungin and [symbol: see text]voriconazole for fungal infections.
    Drug Ther Bull; 2004 Jan; 42(1):5-8. PubMed ID: 14768298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple antifungal therapy for the treatment of invasive aspergillosis in a neutropenic pediatric patient.
    Sims-McCallum RP
    Am J Health Syst Pharm; 2003 Nov; 60(22):2352-6. PubMed ID: 14652986
    [No Abstract]   [Full Text] [Related]  

  • 6. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
    Moen MD; Lyseng-Williamson KA; Scott LJ
    Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis.
    Clemons KV; Espiritu M; Parmar R; Stevens DA
    Antimicrob Agents Chemother; 2005 Dec; 49(12):4867-75. PubMed ID: 16304147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New developments in antifungal therapy: fluconazole, itraconazole, voriconazole, caspofungin].
    van 't Wout JW; Kuijper EJ; Verweij PE; Kullberg BJ
    Ned Tijdschr Geneeskd; 2004 Aug; 148(34):1679-84. PubMed ID: 15453120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic mycoses in the immunocompromised host: an update in antifungal therapy.
    Kontoyiannis DP; Mantadakis E; Samonis G
    J Hosp Infect; 2003 Apr; 53(4):243-58. PubMed ID: 12660121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caspofungin versus liposomal amphotericin B for empirical therapy.
    Danaher PJ
    N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675092
    [No Abstract]   [Full Text] [Related]  

  • 11. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage.
    Spanakis EK; Aperis G; Mylonakis E
    Clin Infect Dis; 2006 Oct; 43(8):1060-8. PubMed ID: 16983621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An update on the use of antifungal agents.
    Martinez R
    J Bras Pneumol; 2006; 32(5):449-60. PubMed ID: 17268750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination antifungal therapy: where are we now, and where are we going?
    Marr K
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 7):24-9. PubMed ID: 15651179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
    Walsh TJ; Teppler H; Donowitz GR; Maertens JA; Baden LR; Dmoszynska A; Cornely OA; Bourque MR; Lupinacci RJ; Sable CA; dePauw BE
    N Engl J Med; 2004 Sep; 351(14):1391-402. PubMed ID: 15459300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Voriconazole versus amphotericin B in cancer patients with neutropenia.
    Jørgensen KJ; Gøtzsche PC; Johansen HK
    Cochrane Database Syst Rev; 2006 Jan; (1):CD004707. PubMed ID: 16437492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis.
    Keating G; Figgitt D
    Drugs; 2003; 63(20):2235-63. PubMed ID: 14498760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Voriconazole: review of a broad spectrum triazole antifungal agent.
    Kofla G; Ruhnke M
    Expert Opin Pharmacother; 2005 Jun; 6(7):1215-29. PubMed ID: 15957974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia.
    Jørgensen KJ; Gøtzsche PC; Dalbøge CS; Johansen HK
    Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD004707. PubMed ID: 24563222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amphotericin B lipid complex in pediatric patients with invasive fungal infections.
    Walsh TJ; Seibel NL; Arndt C; Harris RE; Dinubile MJ; Reboli A; Hiemenz J; Chanock SJ
    Pediatr Infect Dis J; 1999 Aug; 18(8):702-8. PubMed ID: 10462340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Drugs used in prophylaxis and treatment of fungal infections in immunosuppressed children].
    Balwierz W
    Przegl Lek; 2004; 61 Suppl 2():89-94. PubMed ID: 15686055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.